We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Associates of Cape Cod (ACC) and MDS Analytical Technologies Collaborate

Read time: 1 minute

ACC and MDS Analytical Technologies collaborated on an FDA 21 CFR part 11 solution for ACC’s Chromogenic LAL Endotoxin assay kits. The partnership was based on ACC’s validation of MDS Analytical Technologies’ VersaMax™ monochromator-based absorbance microplate reader using the SoftMax® Pro GxP software compliant environment.

ACC offers several chromogenic assays:  Pyrochrome® and Chromo-LAL for endotoxin detection and Glucatell® to detect (1,3)-ß-D-glucan in industrial applications.  All methods are optimized for use in microplate detection systems such as the VersaMax™ reader.

SoftMax® Pro 5 GxP software from MDS Analytical Technologies is the industry standard microplate analysis software, offering extensive data capture and analysis capabilities in a FDA 21 CFR Part 11 compliant environment for MDS Analytical Technologies’ SpectraMax® line of microplate readers. It includes features that make it particularly well suited to endotoxin and glucan assays.

“We are proud to partner with one of the world’s largest manufacturers of assay kits to detect endotoxin in drugs and biological products”, said Andy Boorn, President of MDS Analytical Technologies. “Our pharmaceutical and biotechnology customers performing tests on the SpectraMax instrument platform can now increase their capital asset utilization by running LAL assays on SpectraMax readers. In addition, they can leverage the FDA 21 CFR Part 11 compliant system setup with SoftMax Pro GxP software reducing additional compliance costs required with third-party vendor solutions.”

ACC President & CEO A.J. Meuse, Ph.D. added, “Partnering with MDS Analytical Technologies, one of the premier bioanalytical instrument companies in the world, further strengthens our ability to meet the variety of  instrument and software requirements our customers have for endotoxin and (1,3)-ß-D-glucan analysis.  We are pleased to offer our customers the VersaMax™ plate reader which provides additional functionality for product release testing in an FDA 21 CFR Part 11 compliant environment.”

Customized assay methods for Chromo-LAL, Glucatell®, Glucatell®Diazo, Pyrochrome®, Pyrochrome® Diazo assay kits are available for SoftMax® Pro software version 5.2 GxP and greater.

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.